Apolipoprotein A4 Restricts Diet‐Induced Hepatic Steatosis via SREBF1‐Mediated Lipogenesis and Enhances IRS‐PI3K‐Akt Signaling

Abstract

ApoA4 restricts hepatic steatosis by inhibiting SREBF1-mediated lipogenesis and improves insulin sensitivity and glucose uptake via IRS-PI3K-Akt signaling in the liver. These findings indicate that ApoA4 may serve as a therapeutic target for obesity-associated NAFLD.